Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2026 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
March 16, 2026 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment
February 24, 2026 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359
February 23, 2026 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
January 08, 2026 22:49 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
January 07, 2026 16:01 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 07, 2026 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
January 06, 2026 16:05 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
December 16, 2025 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate,...
December 15, 2025 16:01 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results